Abstract
Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19.
Keywords: Anti-IL6 receptor; COVID-19; MOGAD; Monoclonal antibody; SARS-CoV-2; Tocilizumab.
【저자키워드】 COVID-19, SARS-CoV-2, Tocilizumab, monoclonal antibody, MOGAD, Anti-IL6 receptor, 【초록키워드】 Tocilizumab, Infection, Asymptomatic, Patient, receptor, survival rate, respiratory, disease, high risk, Oligodendrocyte, anti-IL6, Prevent, tested, affected, the patient, demyelinating disorder, Myelin, subgroup of patient, treatment with tocilizumab, 【제목키워드】 Treatment, Tocilizumab, SARS-COV-2 infection, disorder, Benign,